Chronic Kidney Disease

Digital Education Hubs

The gradual loss of renal function related to cardiometabolic decline is the body’s response to inflammation, high blood pressure, obesity, tobacco and alcohol use, uncontrolled blood glucose, and other acquired (noncongenital) and lifestyle factors. Therapeutic options to preserve kidney function can slow disease progression and reduce burden.

CME/CE Activities
Available courses, certification information, and the latest educational opportunities for practitioners interested in beginning or continuing their careers in a cardiometabolic subspecialty with emphasis on chronic kidney disease.

News Digest

The latest industry news, CMHC Pulse Blogs and Cardiometabolic Chronicle articles related to chronic kidney disease.
Chronic Kidney Disease

Potassium: What We Know Now

Because Cardiometabolic Health Conference (CMHC) is committed to keeping busy providers well-informed on the most current developments affecting their practice, this week’s Pulse Blog focuses

Read More »
Chronic Kidney Disease

Potassium: Helpful or Harmful?

Potassium-rich foods like bananas, avocados, tomatoes, and squash are generally regarded as healthful, especially for lowering blood pressure and improving cardiovascular health. However, patients with

Read More »

article

Atherosclerosis/Thrombosis

article

Atherosclerosis/Thrombosis

article

Atherosclerosis/Thrombosis

article

Cardiometabolic Disease

The experts behind Cardiometabolic Health Congress have identified 10 stories in cardiorenal medicine to watch in 2023.

article

Cardiometabolic Disease

The experts at Cardiometabolic Health Congress (CMHC) have selected the TOP 10 developments, approvals, news, and findings from 2022 that impact the field of cardiorenal

article

Chronic Kidney Disease

The experts at Cardiometabolic Health Congress are honored to be in attendance at Kidney Week 2022 in Orlando, Fl.

article

Atherosclerosis/Thrombosis

Hundreds of practitioners gathered at the Boston Park Plaza for the annual conference from Cardiometabolic Health Congress (CMHC) on Oct. 19-22, 2022. Founded in 2006,
Expert Highlights and Perspectives
A cache of recorded faculty presentations addressing the diagnosis, clinical management, treatment, and emerging strategies related to chronic kidney disease.

Iron Deficiency Anemia in Non-Dialysis Dependent Chronic Kidney Disease- An Overview​

Orlando M. Gutierrez, MD

Watch Dr. Gutierrez discuss:

  • The interplay between IDA and CKD
  • Burden of ID and IDA on patients with NDD-CKD
  • Overview of iron physiology

Recognizing IDA in NDD CKD Challenges, Current Recommendations, and Emerging Approaches​

Ellie Kelepouris, MD

Watch Dr. Kelepouris discuss the following points:

  • Signs of symptoms of IDA
  • Challenges of identifying IDA in NDD-CKD
  • Initial evaluation of IDA
  • Current measures: TSAT, serum ferritin, others
  • What do the kidney guidelines say about screening/diagnosis of IDA

IV Iron Therapy for Non-dialysis CKD​

Kamyar Kalantar-Zadeh, MD

Watch Dr. Kalantar-Zadeh highlighting the following points:

  • Current challenges in the treatment of IDA in NDD-CKD
  • Different modalities for iron repletion in NDD-CKD patients with IDA
  • Available iv iron agents for IDA in NDD-CKD

Challenging Cases in NDD-CKD Patients With IDA​

Orlando M. Gutierrez, MD
Ellie Kelepouris, MD
Kamyar Kalantar-Zadeh, MD

Watch the following three cases where Drs. Gutierrez, Kelepouris, and Kalantar-Zadeh discuss the practical management of an NDD-CKD patient with IDA.

Interpreting New Evidence with Novel Non-Steroidal MRA's for Cardiorenal Risk Reduction

Rajiv Agarwal, MD
Rajiv Agarwal, MD
George L. Bakris, MD
George L. Bakris, MD
Bertram Pitt, MD

Watch the experts share some highlights including:

New and ongoing studies with novel non-steroidal MRAs in addressing cardiorenal risk, including in patients with heart failure and in those with non-diabetic kidney disease. 

Evaluating the Risk For DKD Progression

George L. Bakris, MD
George L. Bakris, MD
Janet B. McGill, MD
Janet McGill, MD

Watch the experts share some highlights including:

  • Early recognition and screening for DKD
  • Monitoring kidney function
  • Risk factors for DKD progression

The Rationale For Non-Steroidal MRAS In DKD

George L. Bakris, MD
George L. Bakris, MD
Rajiv Agarwal, MD
Rajiv Agarwal, MD

Watch the experts share some highlights including:

  • Differentiating between steroidal and non-steroidal MRAs
  • Adverse events and limitations with steroidal MRAs in DKD
  • Advantages of finerenone in DKD
  • The overview of kidney results of the FIDELIO trial

The Cardiovascular Benefits of Finerenone

George L. Bakris, MD
George L. Bakris, MD
Rajiv Agarwal, MD
Rajiv Agarwal, MD

Watch the experts share some highlights including:

  • The interplay between the kidney and heart
  • CVD benefits of finerenone: analysis from the FIDELIO trial and ongoing CVD studies with finere none
  • How does finerenone fit within the context of SGLT-2is

Finerenone: Putting the Data Into Context

George L. Bakris, MD
George L. Bakris, MD

Watch the experts share some highlights including:

  • Finerenone in the context of existing treatments
  • Clinical pearls for incorporating finerenone to the DKD treatment armamentarium in the near future
Drug Pipelines
Key emerging approaches for the treatment of chronic kidney disease that are being studied in various stages of clinical trials, or that were recently approved by the U.S. Food and Drug Administration for therapeutic use.

CKD = chronic kidney disease; ESKD = end-stage kidney disease; HIF-PH = hypoxia-inducible factor prolyl hydroxylase; type 2 diabetes

Drug Pipeline Coming Soon

Subscribe

Sign up to receive updates on educational opportunities, complimentary content, exclusive discounts, and more.